Skip to content
← Lobby Directory
AL
Other

ARTERIUM LTD

Kyiv, UKRAINELLCReg: 495352153084-18Since 25/03/2024

Budget

€5 — €0

EP Access

0

accredited persons

Staff

3

0.85 FTE

EU Grants

None

Mission & Goals

We create, manufacture and market high-quality and effective medicines for healthier, longer and more productive lives.

EU Legislative Interests

1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use; 2. Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006; 3. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC; 4. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast); 5. Commission Regulation (EU) 2023/1545 of 26 July 2023 amending Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards labelling of fragrance allergens in cosmetic products; 6. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. And all European regulation about medicines, food supplement, cosmetics and medical devices.

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

Our company is a member of: European Business Association https://eba.com.ua/; Association "Market Operators of Medical Devices," AMOMD® CSR Ukraine (Center social responsibility) https://csr-ukraine.org/

Organisation Members

Our company is affiliated with ARTERIUM CORPORATION

Commissioner Meetings

No recorded meetings with EU commissioners.

ARTERIUM LTD — EU Lobby Register | GovLens